What’s up with the drug channel? Julie Yoo, a general partner at a16z Bio+Health, joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, the editorial lead for a16z Bio+Health, to discuss this question. We talk about PBMs, the 340B drug program, some of the startups working within and around the primary drug channel, and whether there’s room for entrepreneurs to build in such a consolidated space.For additional reading, see some of Adam’s work on his blog, Drug Channels:https://www.drugchannels.net/2022/08/the-340b-program-climbed-to-44-billion.htmlhttps://www.drugchannels.net/2022/04/the-top-pharmacy-benefit-managers-of.htmlhttps://www.drugchannels.net/2020/05/insurers-pbms-specialty-pharmacies.htmlhttps://www.drugchannels.net/2020/08/how-goodrx-profits-from-our-broken.htmlhttps://www.drugchannels.net/2022/10/five-surprising-facts-about-goodrx-and.html